Allergy Therapeutics (AGY) — Cash Flow Reinvestment Rate
Allergy Therapeutics (AGY) has a Cash Flow Reinvestment Rate of 0.31x as of December 2021, reinvesting GBX1.15 Million (capex GBX1.15 Million ) from operating cash flow of GBX3.71 Million. Explore AGY capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Allergy Therapeutics Cash Flow Reinvestment Rate (2003–2021)
Historical reinvestment intensity for Allergy Therapeutics across 11 annual periods. Also explore balance sheet size of Allergy Therapeutics for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Allergy Therapeutics (2003–2021)
Year-by-year capital reinvestment analysis for Allergy Therapeutics. For live market cap and broader valuation context, see Allergy Therapeutics (AGY) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (GBX) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 0.61x | GBX5.20 Million | GBX8.52 Million | GBX2.56 Million | ▲ +48.3% |
| 2020 | 0.41x | GBX5.06 Million | GBX12.28 Million | GBX2.55 Million | ▼ -62.6% |
| 2019 | 1.10x | GBX6.16 Million | GBX5.60 Million | GBX2.81 Million | ▼ -94.3% |
| 2017 | 19.34x | GBX3.44 Million | GBX178.00K | GBX1.50 Million | ▲ +5436.9% |
| 2015 | 0.35x | GBX1.09 Million | GBX3.12 Million | GBX1.09 Million | ▼ -15.5% |
| 2014 | 0.41x | GBX898.00K | GBX2.17 Million | GBX898.00K | ▲ +22.4% |
| 2013 | 0.34x | GBX821.00K | GBX2.43 Million | GBX821.00K | ▼ -22.9% |
| 2012 | 0.44x | GBX1.26 Million | GBX2.88 Million | GBX1.26 Million | ▼ -56.1% |
| 2010 | 1.00x | GBX1.70 Million | GBX1.70 Million | GBX1.70 Million | ▲ +150.2% |
| 2004 | 0.40x | GBX760.00K | GBX1.91 Million | GBX760.00K | ▲ +105.8% |
| 2003 | 0.19x | GBX406.00K | GBX2.10 Million | GBX406.00K | — |